Open Access311.4: Every 2-Month Belatacept Maintenance Therapy in Kidney Transplant Recipients: 3-Year Follow-up of a Randomized, Non-inferiority Trial
Author(s) -
Aileen C. Johnson,
Geeta Karadkhele,
Neeta Shenvi,
Kirk A. Easley,
Christian Larsen,
I. Raul Badell
Publication year - 2022
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/01.tp.0000886380.49829.f4
Subject(s) - medicine , belatacept , dosing , immunosuppression , population , randomized controlled trial , adverse effect , transplantation , kidney transplantation , renal function , urology , post hoc analysis , cumulative incidence , maintenance therapy , incidence (geometry) , surgery , kidney transplant , chemotherapy , physics , environmental health , optics